We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, an... Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, and acquisitions. The company's pipeline consists of product candidates targeting hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue and license revenue. Show more
– Late-breaker SOLSTICE data abstract accepted for poster presentation at the European Association for the Study of the Liver (EASL) Congress 2024 – – Two additional hepatitis program data...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities...
Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the “Board”) at its...
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2024, on May 2, 2024. The...
– Over 60 participants dosed in two additional cohorts; initial data expected in the second quarter – – Approximately 50% of participants have compensated cirrhosis – Vir Biotechnology, Inc...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 2.56 | 33.0749354005 | 7.74 | 10.59 | 7.64 | 1116549 | 8.63190741 | CS |
4 | 1.01 | 10.8719052745 | 9.29 | 10.59 | 7.61 | 880459 | 8.53797866 | CS |
12 | 1 | 10.752688172 | 9.3 | 12 | 7.61 | 1036498 | 9.94773173 | CS |
26 | 1.97 | 23.6494597839 | 8.33 | 12 | 7.61 | 1121171 | 9.73371819 | CS |
52 | -14.43 | -58.3501819652 | 24.73 | 27.48 | 7.61 | 1193919 | 12.51789366 | CS |
156 | -37.92 | -78.6395686437 | 48.22 | 58 | 7.61 | 1150583 | 24.89707488 | CS |
260 | -5.85 | -36.2229102167 | 16.15 | 141.01 | 7.61 | 1128045 | 30.59949375 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions